Try our Advanced Search for more refined results

In Re: National Prescription Opiate Litigation

Track this case

Case overview

Case Number:

1:17-md-02804

See also:

Court:

Ohio Northern

Nature of Suit:

P.I.: Other

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Dan Aaron Polster (MDL 28

Firms

Companies

Government Agencies

Sectors & Industries:

  1. August 06, 2018

    Providers Say Don't Kill Hospital Bellwether In Opioid MDL

    A coalition of 44 hospitals that say they are on the front lines of treating the opioid epidemic on Friday asked to weigh in on multidistrict litigation over the opioid crisis, arguing that efforts to dismiss a bellwether lawsuit for hospitals should be rejected.

  2. August 02, 2018

    Allergan Files 3rd-Party Claims Against Pfizer In Opioid MDL

    Allergan Finance LLC has hit Pfizer Inc. and a subsidiary with third-party claims in multidistrict litigation over the opioid crisis, arguing that Allergan should be indemnified for having to defend pre-2009 misleading marketing allegations relating to a prescription opioid.

  3. August 01, 2018

    Opioid MDL Counties Get Partial Info From McKesson Report

    A special master appointed to oversee a discovery dispute in multidistrict litigation over the opioid crisis partially granted a request by counties for more information from a McKesson Corp. investigation into suspicious drug order oversight, finding Wednesday the counties are entitled to witness names but that statements and terms used in the investigation are protected work product.

  4. July 26, 2018

    Media Can't Access Drug Co. Data In Opioid MDL

    An Ohio federal judge on Thursday blocked media access to voluminous drug company data divulged in multidistrict litigation over the opioid crisis, concluding that publicity would undermine a delicate discovery process in the high-stakes case.

  5. July 25, 2018

    Discovery War Breaks Out In Opioid MDL Bellwethers

    A simmering discovery dispute in multidistrict litigation over the opioid crisis has boiled over, according to court filings late Tuesday that show drugmakers and pharmacies going public with heated objections over the "unprecedented breadth" and "massive scope" of document disclosures.

  6. July 18, 2018

    Discovery In Opioid MDL Bellwethers Gets Big Haircut

    A special master on Tuesday significantly reduced the amount of information that drug companies must divulge as part of bellwether cases in multidistrict litigation over the opioid crisis, calling an earlier disclosure order excessive.

  7. July 17, 2018

    Product Liability Cases To Watch: Midyear Report

    The tsunami of litigation over the nation's deadly opioid crisis will continue to keep attorneys riveted as the parties work toward trial dates next year. And after a string of losses for patients who claim that Bayer failed to warn of its blood thinner Xarelto's bleeding risks, attorneys are looking to see if they can find a winning argument. Here are the product liability cases attorneys will be keeping an eye on for the rest of 2018.

  8. July 09, 2018

    DEA Doubles Down On Protecting Drug Info In Opioid MDL

    The U.S. Drug Enforcement Administration on Monday urged the Ohio federal judge overseeing the massive opioid multidistrict litigation to block public records requests for federal opioid sales data, saying that disclosure raises privacy and law enforcement concerns.

  9. July 06, 2018

    Drug Cos. Assail Hospital Bellwether In Opioid MDL

    Drug companies are directing heavy fire at a bellwether lawsuit for hospitals in multidistrict litigation over the opioid crisis, calling it a "dangerous" case that suggests health care providers can sue any business that harms an uninsured patient.

  10. July 02, 2018

    Drug Cos. In Opioid MDL Must Divulge Vast Data Trove

    Drug manufacturers and distributors must cough up many years of documents related to sales of narcotic painkillers, a special master ruled Saturday in multidistrict litigation over the opioid crisis, shooting down many industry objections.